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Figure. Pulmonary arteriole intimal and medial thickening seen in a patient
with bronchiolitis obliterans
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with BO may assist in diagnosing PH. The treatment for PH
differs from BO and there is little understanding of their
interplay post-HSCT; further investigation is needed.291
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Background: Posterior reversible encephalopathy syndrome
(PRES) is a clinical syndrome characterized by vision
changes, alteredmental status, and seizures that are typically
caused by acute rise in blood pressure and resolve over time.
PRES has been reported after stem cell transplant (SCT) in
association with hypertension from calcineurin inhibitors
and steroids. The radiologic evaluation of PRES after SCT has
not been well described.
Design/Methods: A retrospective review of all cases of PRES
in SCT recipients from January of 2004 to December of 2013
was performed. PRES was diagnosed if the patient developed
encephalopathy, headache, seizures or visual disturbances
with a CT and/or MRI showing imaging ﬁndings compatible
with PRES.
Results: Twenty-two of 838 (2.6%) transplanted patients
were diagnosed with PRES, all of them allogeneic SCT re-
cipients. The majority (64%) were male with a median age of9.4 years (IQR 4.9-12.1) at time of SCT. Nine patients had a
marrow failure syndrome (41%), 7 of which had Fanconi
Anemia; 7 patients had an immune deﬁciency (32%); 5 had
an underlying malignancy (23%); and 1 patient had a meta-
bolic syndrome (4%). Twelve patients (55%) had a myeloa-
blative preparative regimen. All patients received
cyclosporine for graft versus host disease prophylaxis after
SCT and 11 (50%) were treated with additional immunosu-
pressants including steroids for GVHD at the time of event.
PRES was diagnosed at a median of 49 days (IQR 31-88) after
SCT. Nineteen patients (86%) presented with seizures, the
other 3 (14%) had altered mental status. All patients under-
went a brain CT and/or MRI, 21 of 22 patients (95%) received
a CT scan when they became symptomatic, which was
diagnostic of PRES in 8 of the 21 studies (38%). Eighteen
patients (82%) received MRI, 17 of the 18 (96%) were
consistent with PRES. The one MRI not consistent with PRES
was done 20 days after initial diagnosis, subsequent to res-
olution of the abnormal CT ﬁndings. Notably in 13 patients
initial CT scans did not demonstrate ﬁndings of PRES, which
were subsequently found on MRI. The median time elapsed
between CT and an MRI examination was 20 hours (range:
3.6 hours to 9 days). The overall survival in patients that
developed PRES was 35% (8 of 23 survived).
Conclusion: CT scan serves as a good diagnostic test in
emergency situations to rule out CNS bleed or infection in
SCT patients with acute mental status changes or seizures,
but it is not an adequate radiologic study for diagnosing of
PRES after SCT. Patients with clinical symptoms suggestive of
PRES, but negative CT, should undergo MRI of the brain after
the acute event is controlled to assist in diagnosis. MRI re-
sults diagnostic of PRES would prompt physicians to provide
good hypertension control and aid decision-making
regarding invasive diagnostic procedures (like lumbar
puncture) or intensiﬁcation of empiric antimicrobial therapy.292
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Background: The gut microbiome is an important immune
modulator, and previous work has shown important changes
in the gut microbiome associated with the occurrence of
GVHD. Studies in premature babies at risk for necrotizing
enterocolitis have shown that enteral human milk reduces
gut inﬂammation and bacterial translocation (Morrow et al,
2012).We hypothesized that enteral humanmilk given in the
peri-transplant period would be well tolerated and would
modify the microbiome and reduce inﬂammation.
Methods: In a pilot study, we treated 10 children<2 yrs with
donor enteral milk, and collected stool samples for micro-
biome analysis and blood samples for analysis of inﬂamma-
tory markers. Milk was obtained from the Mother’s Milk
Bank of the Northeast. Milk donors underwent standard
donor screening and milk was pasteurized before use. As
prebiotic and anti-inﬂammatory beneﬁts of are thought to
derive from human milk oligosaccharides produced by
fucosyltransferase2 (FUT2) and related gene biosynthesis
Table
Histologic features in patients with TMA and without TMA
HSCT patients with gastrointestinal symptoms (n[50)
TMA/
iGVDH
n¼15
No TMA/
iGVDH
n¼21
No TMA/
no iGVDH
n¼14
p¼value
Figure. Intestinal microangiopathy
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screened to ensure the presence of these oligosaccharides.
Results: Ten children were treated with milk, 8 boys and 2
girls. Ages at transplant ranged from 6 to 40 months. Di-
agnoses included non-malignant hematopoietic disorders
(n¼8) and leukemia (n¼2). Three children had sibling do-
nors, 1 a matched aunt and 6 unrelated donors; all received
bone marrow grafts. Treated cases were compared with 4
young children transplanted in the same time period who
received standard nutrition under the supervision of the
BMT dietician. Milk was given to provide 40% of caloric needs
(as breast milk cannot provide all nutritional needs for
children older than 6 months), from day -3 through day +14
after transplant. Enteral human milk was well tolerated with
all children receiving all the milk planned for administration.
Microbiome analysis showed no differences between study
groups at the start of transplant. Signiﬁcant differences were
observed between milk treated and control patient micro-
biomes at day 10 after transplant, when, consistent with
microbiome changes previously reported with GVHD risk
(Jenq et al 2012), control patients had signiﬁcantly increased
facultative anaerobes Streptococcaceae and Actino-
mycetaceae compared to milk fed patients. Measurement of
sIL2r levels showed elevation of levels at day 14 in controls
compared with cases.
Conclusions: This preliminary study suggests a possible role
for human milk in modulation of the microbiome and
reduction of a pro-inﬂammatory environment and a ran-
domized study is now in progress. Synthetic human milk
oligosaccharides have the potential to extend this strategy to
adults, and are currently being tested in a mouse model of
GVHD.Mucosal hemorrhages 12 (80%) 11 (52.4%) 5 (36%) 0.057
Loss of glands 11 (73.3%) 8 (38%) 0 (0%) <0.0001
Intravascularschistocytes 10 (66.7%) 5 (23.8%) 3 (21.4%) 0.016
Intravascular
ﬁbrinoid debris
8 (53.3%) 2 (9.55%) 2 (14%) 0.008
Intravascularmicrothrombi 4 (26.6%) 0 (0%) 0 (0%) 0.010
Endothelial cell swelling 13 (86.6%) 13 (61.9%) 7 (50%) 0.086
Endothelial cell separation 8 (53.3%) 3 (14.3%) 1 (7%) 0.007
Total denudation
of mucosa
7 (46.7%) 3 (14.3%) 0 (0%) 0.005293
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Introduction: We showed that high risk transplant-associ-
ated thrombotic microangiopathy (TMA) can present with
multisystem involvement and has poor outcome after HSCT
with <20% 1-year survival (Jodele, Blood 2014). TMA may
involve intestinal vasculature and can present with bleeding
and ischemic colitis. There are no established pathologic
criteria for diagnosis of intestinal TMA (iTMA). The goal of
our study was to review available tissue specimens obtained
after HSCT in order to identify histologic features of iTMA.
Methods: Fifty consecutive HSCT patients who underwent
endoscopy for gastrointestinal symptoms were evaluated for
histopathologic signs of iTMA using 8 histologic criteria
described in literature: mucosal hemorrhages, loss of glands,
schistocytes, ﬁbrinoid debris in the vessel lumen, intravas-
cular microthrombi, endothelial cell swelling, endothelial
cell separation and total denudation of mucosa (Figure). The
reviewing pathologist was blinded to patients’ clinical
history. Histologic markers were listed as present or absent.
For patients having multiple evaluations after HSCT, the
ﬁrst diagnostic tissue sample was used for this study.
Patients were divided into 3 clinical groups based on the
presence or absence of systemic TMA and intestinal graft
versus host disease (iGVHD): TMA/iGVHD, no TMA/iGVHD,and noTMA/no iGVHD. Systemic TMA was diagnosed using
rigorous clinical and diagnostic criteria. Comparison among
the groups was done using Fisher exact test.
Results: Fifteen patients (30%) had a clinical diagnosis of
systemic TMA.Out of 35patientswithout TMA, 21had clinical
and histologic evidence of gut GVHD while 14 did not. Inci-
dence of stage 3-4 gut GVHD was similar in the TMA/iGVHd
andnoTMA/iGVHDgroups (79%vs 64%). All histologic signs of
iTMA except for mucosal hemorrhages and endothelial cell
swelling were signiﬁcantly more common in patients with
systemic TMA (p<0.05). Intravascular thrombi were exclu-
sively seen only in patients with systemic TMA (Table).
Conclusions: We identiﬁed histologic features of iTMA that
can be used to delineate vascular injury of the bowel in pa-
tients with TMA after HSCT. Recognition of these histological
signs in patients with gastrointestinal symptoms after HSCT
may guide clinical decisions.
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